18,253 Shares in Lantheus Holdings Inc (LNTH) Acquired by Creative Planning

Share on StockTwits

Creative Planning bought a new position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 18,253 shares of the medical equipment provider’s stock, valued at approximately $447,000.

Other institutional investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its holdings in Lantheus by 51.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 575 shares during the period. Financial Gravity Companies Inc. acquired a new stake in Lantheus in the fourth quarter valued at approximately $45,000. Advisor Group Inc. grew its holdings in Lantheus by 1,837.2% in the fourth quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 4,152 shares during the period. First Quadrant L P CA acquired a new stake in Lantheus in the first quarter valued at approximately $95,000. Finally, Meeder Asset Management Inc. grew its holdings in Lantheus by 212.8% in the first quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 3,236 shares during the period. 93.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of LNTH opened at $24.88 on Thursday. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16. Lantheus Holdings Inc has a 12 month low of $12.59 and a 12 month high of $26.40. The company has a market capitalization of $982.53 million, a price-to-earnings ratio of 26.47, a price-to-earnings-growth ratio of 1.87 and a beta of 1.52.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.28 EPS for the quarter, beating the consensus estimate of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The company had revenue of $86.51 million for the quarter, compared to analyst estimates of $86.80 million. Research analysts anticipate that Lantheus Holdings Inc will post 1.16 earnings per share for the current year.

Several analysts have commented on LNTH shares. BidaskClub raised Lantheus from a “buy” rating to a “strong-buy” rating in a report on Friday, February 22nd. Zacks Investment Research raised Lantheus from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Wednesday, February 20th. TheStreet raised Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. Finally, ValuEngine raised Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.33.

In other news, insider Michael P. Duffy sold 1,789 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $22.77, for a total value of $40,735.53. Following the sale, the insider now directly owns 160,221 shares of the company’s stock, valued at $3,648,232.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director A Frederick Robertson sold 3,932 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $22.77, for a total value of $89,531.64. Following the completion of the sale, the director now directly owns 43,062 shares in the company, valued at $980,521.74. The disclosure for this sale can be found here. Over the last three months, insiders sold 110,102 shares of company stock worth $2,692,548. 2.60% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Equities Focus and is the property of of Equities Focus. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.equitiesfocus.com/2019/05/09/18253-shares-in-lantheus-holdings-inc-lnth-acquired-by-creative-planning.html.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Further Reading: What is a stock split?

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.